Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential.

Cryopreserved human hepatocytes were extensively characterized in our laboratory. The post-thaw viability, measured via dye exclusion, ranged from 55 to 83%, for hepatocytes cryopreserved from 17 donors. Post-thaw viability and yield (viable cells per vial) were found to be stable up to the longest storage duration evaluated of 120 days. Drug-metabolizing enzyme activities of the cryopreserved hepatocytes (mean of ten donors) as percentages of the freshly isolated cells were: 97%, for cytochrome P450 isoform (CYP) 1A2, 78% for CYP2A6, 96% for CYP2C9. 86% for CYP2Cl9, 90% for CYP2D6, 164% for CYP3A4, 76% for UDP-glucuronidase, and 88% for umbelliferone sulfotransferase. Known species-differences in 7-ethoxycoumarin (7-EC) metabolism were reproduced by cryopreserved hepatocytes from human, rat, rabbit, dog, and monkey, illustrating the utility of cryopreserved hepatocytes from multiple animal species in the evaluation of species-differences in drug metabolism. Higher throughput screening (HTS) assays were developed using cryopreserved human hepatocytes for hepatotoxicity, metabolic stability, and inhibitory drug-drug interactions. Dose-dependent cytotoxicity, measured using MTT metabolism as an endpoint, was observed for the known hepatotoxic chemicals tamoxifen, clozapine, cadmium chloride, diclofenac, amiodarone, tranylcypromine, precocene II, but not for 2-thiouracil. Cell density- and time-dependent metabolism of 7-EC and dextromethorphan were observed in the HTS assay for metabolic stability. Known CYP isoform-specific inhibitors were evaluated in the HTS assay for inhibitory drug-drug interactions. Furafylline, sulfaphenazole, quinidine, and ketoconazole were found to be specific inhibitors of CYP1A2, CYP2C9, CYP2D6, and CYP3A4, respectively. Tranylcypromine and diethyldithiocarbamate were found to be less specific, with inhibitory effects towards several CYP isoforms, including CYP2A6, CYP2C9, CYP2C19, and CYP2E1. These results suggest that cryopreserved human hepatocytes represent a useful experimental tool for the evaluation of drug metabolism, toxicity, and inhibitory drug-drug interaction potential.

[1]  R. Obach,et al.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[2]  T. Cyr,et al.  Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[3]  J. Caldwell,et al.  Cryopreservation of rat and mouse hepatocytes. II. Assessment of metabolic capacity using testosterone metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[4]  J. Bridges,et al.  Preparation and properties of primary maintenance cultures of adult rabbit hepatocytes. , 1982, Toxicology.

[5]  Albert P. Li,et al.  Isolation and culturing of hepatocytes from human livers , 1992 .

[6]  Albert P. Li,et al.  The Scientific Basis of Drug-Drug Interactions: Mechanism and Preclinical Evaluation , 1998 .

[7]  P. Olinga,et al.  Influence of 48 hours of cold storage in University of Wisconsin organ preservation solution on metabolic capacity of rat hepatocytes. , 1997, Journal of hepatology.

[8]  R. Ad,et al.  Application of Human Liver Microsomes in Metabolism-Based Drug-Drug Interactions: In Vitro-in Vivo Correlations and the Abbott Laboratories Experience , 1997 .

[9]  A. Li,et al.  Optimization of cryopreservation procedures for rat and human hepatocytes. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  C. Ioannides,et al.  Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen. , 1998, Environmental health perspectives.

[11]  H. W. Ruelius.  Extrapolation from animals to man: predictions, pitfalls and perspectives. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[13]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[14]  D. Jenden.  Difficulties in using animal data to predict pharmacological response in man , 1991, Neuroscience & Biobehavioral Reviews.

[15]  M H Tarbit,et al.  High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. , 1998, Current opinion in chemical biology.

[16]  Albert P. Li,et al.  Drug-drug interactions : Scientific and regulatory perspectives , 1997 .

[17]  A. Li,et al.  Comparative metabolism of SC-42867 and SC-51089, two PGE2 antagonists, in rat and human hepatocyte cultures. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. , 1996, Toxicology in vitro : an international journal published in association with BIBRA.

[19]  J. Richburg,et al.  Preservation of the rate and profile of xenobiotic metabolism in rat hepatocytes stored in liquid nitrogen. , 1993, Biochemical pharmacology.

[20]  S. Gad.  In Vitro Toxicology , 2000 .

[21]  T. Green.  Species differences in carcinogenicity: the role of metabolism in human risk evaluation. , 1990, Teratogenesis, carcinogenesis, and mutagenesis.

[22]  P. Olinga,et al.  Effect of cold and warm ischaemia on drug metabolism in isolated hepatocytes and slices from human and monkey liver. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  M. Wang,et al.  Effective cryopreservation and long-term storage of primary human hepatocytes with recovery of viability, differentiation, and replicative potential. , 1995, Cell transplantation.

[24]  D. Utesch,et al.  Metabolic activity of fresh and cryopreserved dog hepatocyte suspensions. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  F. Guengerich.  Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. , 1997, Chemico-biological interactions.